Literature DB >> 24984533

Whole-body [18F]fluoro-2-deoxyglucose positron emission tomography scan as combined PET-CT staging prior to planned radical vulvectomy and inguinofemoral lymphadenectomy for squamous vulvar cancer: a correlation with groin node metastasis.

M W Kamran, F O'Toole, K Meghen, A N Wahab, F A Saadeh, N Gleeson.   

Abstract

Surgery is the mainstay of treatment for vulvar cancer. FIGO staging requires histopathological detail of the primary tumor and inguinofemoral lymph nodes but groin node dissection carries a substantial risk of short and long-term morbidity. The trend in current practice is towards sentinel lymphadenectomy for cancers with a low risk of metastases. Full lymphadenectomy is undertaken if the sentinel lymph node contains metastasis. The predictive value of 18F-FDG-PET in preoperative assessment of the groin in vulvar squamous cancer was assessed in retrospect at a single institution. A period of three years prior to the introduction of sentinel lymph node mapping was chosen in order to have full histopathological assessment of inguinal and femoral lymph nodes available as the gold standard for correlation with positron emission tomography-computerized tomography (PET-CT) to determine the accuracy of the enhanced radiological technique. In patients with histologically proven metastases to groin nodes, comparisons between PET-CT positive (True-positive/TP) and negative (False-negative/FN) groups vis-à-vis histology showed a tendency towards higher FDG avidity in the vulvar lesions, more bilateral nodes, multiple metastases, larger metastases and more extra-capsular extension in the TP group. Calculations per patient for PET-CT yielded a sensitivity of 50% and specificity at 100%. The positive predictive value (PPV) was 100% and the negative predictive value (NPV) was 57.1%. The test accuracy was 70% per patient. The high positive predictive value of PET-CT can be used to advance treatment planning prior to surgical staging of patients identified with Stage III disease. The poor sensitivity makes it unsuitable as a substitute for staging lymphadenectomy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24984533

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  6 in total

1.  The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer.

Authors:  N L Robertson; H Hricak; Y Sonoda; R E Sosa; M Benz; G Lyons; N R Abu-Rustum; E Sala; H A Vargas
Journal:  Gynecol Oncol       Date:  2016-01-11       Impact factor: 5.482

Review 2.  The Role of Ultrasound in the Evaluation of Inguinal Lymph Nodes in Patients with Vulvar Cancer: A Systematic Review and Meta-Analysis.

Authors:  Debora Verri; Francesca Moro; Simona Maria Fragomeni; Drieda Zaçe; Sonia Bove; Federica Pozzati; Benedetta Gui; Giovanni Scambia; Antonia Carla Testa; Giorgia Garganese
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

Review 3.  The giant steps in surgical downsizing toward a personalized treatment of vulvar cancer.

Authors:  Andrea Giannini; Ottavia D'Oria; Benito Chiofalo; Valentina Bruno; Ermelinda Baiocco; Emanuela Mancini; Rosanna Mancari; Cristina Vincenzoni; Giuseppe Cutillo; Enrico Vizza
Journal:  J Obstet Gynaecol Res       Date:  2021-12-28       Impact factor: 1.697

4.  Positron emission tomography-computed tomography for inguinal nodes in vulvar cancer.

Authors:  Jorge Daniel Oldan; Stephanie A Sullivan
Journal:  World J Nucl Med       Date:  2018 Jul-Sep

5.  State of the art in vulvar cancer imaging.

Authors:  Maria Ana Serrado; Mariana Horta; Teresa Margarida Cunha
Journal:  Radiol Bras       Date:  2019 Sep-Oct

6.  Diagnostic performance of preoperative [18F]FDG-PET/CT for lymph node staging in vulvar cancer: a large single-centre study.

Authors:  Vittoria Rufini; Giorgia Garganese; Francesco P Ieria; Tina Pasciuto; Simona M Fragomeni; Benedetta Gui; Anita Florit; Frediano Inzani; Gian Franco Zannoni; Giovanni Scambia; Alessandro Giordano; Angela Collarino
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-23       Impact factor: 9.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.